Equities

Travere Therapeutics Inc

17R:BER

Travere Therapeutics Inc

Actions
  • Price (EUR)17.70
  • Today's Change0.20 / 1.14%
  • Shares traded211.00
  • 1 Year change+237.14%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments567450553
Total Receivables, Net211716
Total Inventory9.416.927.31
Prepaid expenses19136.47
Other current assets, total0----
Total current assets617486583
Property, plant & equipment, net263034
Goodwill, net0.750.940.94
Intangibles, net104144147
Long term investments------
Note receivable - long term------
Other long term assets421111
Total assets789673777
LIABILITIES
Accounts payable421715
Accrued expenses987452
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total385157
Total current liabilities178142124
Total long term debt377376227
Total debt377376227
Deferred income tax------
Minority interest------
Other liabilities, total33112124
Total liabilities588630475
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,3281,0601,069
Retained earnings (accumulated deficit)(1126)(1014)(766)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.46)(2.91)(0.56)
Total equity20143302
Total liabilities & shareholders' equity789673777
Total common shares outstanding756462
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.